Evidence map›Paper›PMID 29374236›Full record

ArticleScientific reports2018

SOX2 activation predicts prognosis in patients with head and neck squamous cell carcinoma.

Ji Hyun Chung, Hae Rim Jung, Ah Ra Jung, Young Chan Lee, Moonkyoo Kong, Ju-Seog Lee, Young-Gyu Eun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Vocal folds irregular mucosal changes: a multimodal evaluation for diagnosis and genetic risk stratification.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ji Hyun ChungDepartment of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, South Korea.
Hae Rim JungDepartment of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, South Korea.
Ah Ra JungDepartment of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, South Korea.ORCID http://orcid.org/0000-0001-5647-1184
Young Chan LeeDepartment of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, South Korea.
Moonkyoo KongDepartment of Radiation Oncology, School of Medicine, Kyung Hee University, Seoul, South Korea.
Ju-Seog LeeDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Young-Gyu EunDepartment of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyung Hee University, Seoul, South Korea. ygeun@khu.ac.kr.ORCID http://orcid.org/0000-0003-4081-5207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SOX2 copy number and mRNA expression were analysed to examine the clinical significance of SOX2 activation in HNSCC. Gene expression signatures reflecting SOX2 activation were identified in an HNSCC cohort. Patients with HNSCC were classified into two subgroups according to the gene expression signature: SOX2-high and SOX2-low. The clinical significance of SOX2 activation was further validated in two independent cohorts. Moreover, clinical significance of SOX2 activation in response to radiotherapy was assessed in patients with HNSCC. The relationship between SOX2 activation and radiotherapy was validated in an in vitro experiment. Patients in the SOX2-high subgroup had a better prognosis than patients in the SOX2-low subgroup in all three patient cohorts. Results of multivariate regression analysis showed that SOX2 signature was an independent predictor of the overall survival of patients with HNSCC (hazard ratio, 1.45; 95% confidence interval, 1.09-1.92; P = 0.01). Interestingly, SOX2 activation was a predictor of therapy outcomes in patients receiving radiotherapy. Moreover, SOX2 overexpression enhanced the effect of radiotherapy in HNSCC cell lines. SOX2 activation is associated with improved prognosis of patients with HNSCC and might be used to predict which patients might benefit from radiotherapy.

Indexed as

Gene DosageAgedCarcinoma, Squamous CellFemaleGene Expression ProfilingHead and Neck NeoplasmsHumansMaleMiddle AgedPrognosisRNA, MessengerSOXB1 Transcription FactorsSurvival AnalysisTreatment OutcomeRNA, MessengerSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID29374236
PMCPMC5785960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.